Compare IDYA & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | PBH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2019 | 2004 |
| Metric | IDYA | PBH |
|---|---|---|
| Price | $32.46 | $57.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 3 |
| Target Price | $52.86 | ★ $75.33 |
| AVG Volume (30 Days) | ★ 1.5M | 515.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | 2.88 |
| EPS | N/A | ★ 2.78 |
| Revenue | $218,710,000.00 | ★ $975,777,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $199.11 | $4.31 |
| P/E Ratio | ★ N/A | $20.67 |
| Revenue Growth | ★ 3024.43 | 36.77 |
| 52 Week Low | $16.81 | $51.24 |
| 52 Week High | $39.28 | $88.00 |
| Indicator | IDYA | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 43.21 |
| Support Level | $29.29 | $57.25 |
| Resistance Level | $34.76 | $63.56 |
| Average True Range (ATR) | 2.09 | 2.11 |
| MACD | 0.12 | 0.32 |
| Stochastic Oscillator | 30.74 | 67.41 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.